China Resources Pharmaceutical Group Limited provided earnings guidance for the six months ended 30 June 2023. For the period, the company expects that the net profit attributable to the shareholders of Dong- E-E-Jiao is estimated to range from approximately RMB 510 million to RMB 550 million, representing an increase between approximately 65% and 78% as compared to that of approximately RMB 308.2624 million for the same period last year, net profit excluding non-recurring gain or loss is estimated to range from approximately RMB 470 million to RMB 510 million, representing an increase between approximately 76% and 91% as compared to that of approximately RMB 266.8777 million for the same period last year, and basic earnings per share is estimated to range from approximately RMB 0.79 per share to approximately RMB 0.85 per share (as compared to that of approximately RMB 0.4787 per share for the same period last year).